Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a new Bioprocessing Production Center located in Daejeon, South Korea. This initiative stands as the most significant investment by Merck’s Life Science business sector in the Asia-Pacific region to date, underscoring the company’s dedication to expanding its operations […]
MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has earmarked an investment exceeding €300 million for the establishment of a new Bioprocessing Production Center in Daejeon, South Korea. This significant investment underscores the company’s dedication to enhancing its capabilities within the rapidly evolving Asia-Pacific region, marking its […]
